AHCA Logo

Evidence

Setting the Record Straight
The report is in follow up to the Florida Department of Health’s April 20, 2022 guidance detailing the lack of conclusive evidence in recent directives and “fact sheets” issued by the US Department of Health and Human Services for the coverage of “gender affirming” care, for children and adolescents.

Evidence Evidence
EMINENCE: All medical experts agree on that "gender affirming" care is medically necessary, effective, and safe to alleviate gender dysphoria.
EVIDENCE: The evidence suggesting improvements in gender dysphoria, depression, anxiety, quality of life, and low rates of adverse events, after treatment with puberty blockers and cross-sex hormones is low and very low certainty.

EMINENCE: Using cross-sex hormones is safe and the physical changes are completely reversible.
EVIDENCE: Cross-sex hormonal treatments create changes in body, face, voice tone, and hair development that are irreversible.

EMINENCE: Puberty blockers are not harmful, and their effects are easily reversible. Using puberty blockers will “buy time” for minors who are questioning their gender.
EVIDENCE: The U.S. Food and Drug Administration has not approved any medication that is clinically indicated for the treatment of gender dysphoria. There is no evidence of the long-term effects of puberty blockers on sexual function. Sex hormones also have an important and lasting effect on brain development and adolescent psychology.